Holen Sie sich die Stockscreener-App
7.99
4.99%
-0.42
Handel nachbörslich:
8.23
0.24
+3.00%
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
4D Molecular Therapeutics (NASDAQ:FDMT) Earns Underweight Rating from Analysts at Morgan Stanley - MarketBeat
FY2024 Earnings Forecast for FDMT Issued By Leerink Partnrs - MarketBeat
HC Wainwright Has Negative Outlook for FDMT FY2024 Earnings - MarketBeat
4D Molecular Therapeutics’ Positive Q3 and Strategic Advances - TipRanks
RA Capital Management, L.P. Increases Stake in 4D Molecular Ther - GuruFocus.com
Janus Henderson Group PLC's Strategic Adjustment in 4D Molecular Therapeutics Inc Holdings - GuruFocus.com
Analyst Expectations For 4D Molecular Therapeutics's Future - Benzinga
Deep Track Capital, LP Increases Stake in 4D Molecular Therapeutics Inc - GuruFocus.com
4D Molecular Sets Major Conference Schedule: Jefferies, Evercore & OIS XIV Appearances | FDMT Stock News - StockTitan
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates - MSN
4D Molecular Therapeutics Inc Reports Q3 2024 EPS of $(0.79) and Revenue of $3,000 - GuruFocus.com
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4D Molecular Reports Positive AMD Trial Data, $551M Cash Position Funds Operations to 2027 | FDMT Stock News - StockTitan
4D Molecular Therapeutics stock hits 52-week low at $7.9 By Investing.com - Investing.com Australia
4D Molecular Therapeutics stock hits 52-week low at $7.9 - Investing.com India
4D Molecular Therapeutics Inc. (FDMT) Quarterly 10-Q Report - Quartz
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $47.14 Consensus PT from Analysts - MarketBeat
BioSpace Announces 2025 Best Places to Work in Biopharma - BioSpace
X-Linked Retinitis Pigmentosa Clinical Trials 2024: FDA - openPR
Goldman Sachs Group Inc's Strategic Reduction in 4D Molecular Th - GuruFocus.com
Vanguard Group Inc's Strategic Acquisition of Shares in 4D Molec - GuruFocus.com
We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely - Yahoo Finance
Fabry Disease Market to grow at a CAGR of ~6% by 2032, analyzes - openPR
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Down 13.2% in October - MarketBeat
Assenagon Asset Management S.A. Has $16.68 Million Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
Shareholders Are Encouraged To Join An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations - StockTitan
nVerses Capital LLC Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts
4D Molecular Therapeutics stock hits 52-week low at $8.52 By Investing.com - Investing.com Australia
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
4D Molecular Therapeutics stock hits 52-week low at $8.52 - Investing.com India
Gene therapy for managing neovascular macular degeneration - Ophthalmology Times Europe
Recent Insider Activity Suggests Potential Gains for 4D Molecular Therapeutics Inc (FDMT) - Knox Daily
4D Molecular Therapeutics Inc (FDMT)’s Day in Review: Closing at 9.17, Up by 5.04 - The Dwinnex
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? - Yahoo Finance
Prospect Capital Corp [PSEC] Investment Guide: What You Need to Know - Knox Daily
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Stock Is A Good Option To Consider - Stocks Register
Looking For A Top Momentum Stock? Check Out Service Properties Trust (NASDAQ: SVC) - Stocks Register
Metrics That Matter About Roper Technologies Inc (NASDAQ: ROP) - Stocks Register
FTAI Infrastructure Inc (NASDAQ: FIP) Is A Blank Check For Growth - Stocks Register
This trade activity should not be overlooked: 4D Molecular Therapeutics Inc (FDMT) - SETE News
4D Molecular Therapeutics Inc (FDMT)’s stock decline to 9.26 per share - US Post News
4D Molecular Therapeutics Inc (FDMT) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
4D Molecular Therapeutics stock hits 52-week low at $9.41 By Investing.com - Investing.com UK
Market Insights: 4D Molecular Therapeutics Inc (FDMT)’s Notable Drop of -3.58, Closing at 9.97 - The Dwinnex
Cantor Fitzgerald Downgrades 4D Molecular Therapeutics Inc (FDMT) to a Neutral from an Overweight - Knox Daily
Dimensional Fund Advisors LP Sells 216,250 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 3.8%What's Next? - MarketBeat
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy FailureI'm Not So Sure - Seeking Alpha
4D Molecular Therapeutics, Inc. Is Being Investigated For Possib - WICZ
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Acquired by Squarepoint Ops LLC - MarketBeat
Marshall Wace LLP Trims Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
4D-710 gene therapy helps overcome lack of response to CFTR modulators - BioWorld Online
Take off with 4D Molecular Therapeutics Inc (FDMT): Get ready for trading - SETE News
Investor’s Toolkit: Key Ratios for Assessing 4D Molecular Therapeutics Inc (FDMT)’s Performance - The Dwinnex
4D Molecular Therapeutics' SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com Australia
Profund Advisors LLC Decreases Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):